Research from the ORBITA-2 trial suggests that patients with focal coronary disease may benefit more from percutaneous coronary intervention (PCI) than those with diffuse disease. The study's findings indicate that the type of coronary artery disease can influence the outcomes of PCI in patients with stable angina. Physiologic testing, such as fractional flow reserve (FFR), may help identify which patients are most likely to experience relief from angina after undergoing PCI.